Mark Shamoun
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Hemoglobinopathies and Related Disorders, Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Blood groups and transfusion, Iron Metabolism and Disorders
Most-Cited Works
- → Intravenous Ferric Carboxymaltose in Children with Iron Deficiency Anemia Who Respond Poorly to Oral Iron(2016)84 cited
- → Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up(2024)34 cited
- → Characterizing bulk rigidity of rigid red blood cell populations in sickle-cell disease patients(2021)19 cited
- → Avian Metapneumovirus Subtype B Experimental Infection and Tissue Distribution in Chickens, Sparrows, and Pigeons(2011)16 cited
- → Childhood B-Cell Acute Lymphoblastic Leukemia Following SARS CoV-2 Infection: A Potential Second “Hit” in Leukemogenesis(2020)14 cited
- → CD14/16 monocyte profiling in juvenile myelomonocytic leukemia(2020)7 cited
- → OA14.05 5-Year Survival of Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With PD-L1 Tumor Proportion Score <1%(2023)7 cited
- → The Effect of Azithromycin on Relapse in Patients with Moderate-Severe Chronic Graft Versus Host Disease (CGVHD)(2019)6 cited
- → The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC(2024)6 cited
- → Real-world outcomes on platinum-containing chemotherapy for EGFR-mutated advanced nonsquamous NSCLC with prior exposure to EGFR tyrosine kinase inhibitors(2024)6 cited